RESOURCES
WHITEPAPERS
AI and generative AI are transforming clinical trials by automating data integration, cleaning, and visualization, improving efficiency and accuracy. Advanced tools like predictive analytics, NLP, and RPA enhance data insights and enable adaptive trial designs. These technologies address challenges in data review, imaging, and patient engagement, streamlining operations and improving outcomes across therapeutic areas.
Key Drivers to Improve Data Interoperability in Decentralized Clinical Trials
Sponsors, CROs, eClinical partners, and sites all struggle with data interoperability, even though the tools that they use may have APIs; they have the data, but they can’t make it all work together. With the advent of new Digital Health Technologies (DHTs) and expanding use of EMR/EHR and eSources, the pharmaceutical industry has witnessed tens of millions of data points being captured per study in very short time periods. This was recently re-affirmed in SCDM’s white paper, The 5Vs of Clinical Data, the Society notes, “today we measure m-Health data points in the billions.”
The increasing variety and velocity of clinical data combined with heavy regulatory emphasis on holistic oversight with a 360-degree view of all study data is of the highest strategic importance to sponsors. Data volume and the increased demand for near real-time reporting and visualization requires integration of data across the spectrum of study vendors (eClinical like EDC and CTMS, IRT, mHealth, CROs, core labs and EHR/ EMR). Adaptive Clinical System’s eClinical Solution is designed to deliver a unified data solution for sponsors and CROs that seamlessly and intelligently brings together disparate data for faster, better trial execution and compliance.
Today every company is a digital company. Rapidly evolving technology, new business models, regulatory uncertainty and changing payment models, combined with stringent demands from regulators and customers make build versus buy decisions critical and of major strategic importance, far beyond a simple cost comparison. Register to download this free white paper and gain some strategic insight on best practices for development decision-making, before you build or buy.
It’s 2020 and with that comes a revolution of sorts, one that requires we change our business processes from outdated EDC plus paper-driven procedures to the eSource world. To clarify, in this paper the concept of eSource means that now we electronically capture data at the point of visit instead of manually capturing it. And even though many of us are using EDCs and such, it is no longer
enough.
What are the major challenges facing research organizations today? Every company is a digital company trying to keep up. Every day new tools and solutions become available. Increasingly complex study protocols, ePRO and wearables add to the data deluge. Increasing sponsor involvement, more stringent privacy demands from regulators and patients, and too many unconnected solutions can result in high error rates, inconsistent audit logs, and needs to reduce time and labor – doing more with less.
With the help of Forbes, Frost & Sullivan and a few other healthcare sources, we’re looking ahead to 2019 and sharing some top trends for healthcare. Looking back to 2018, it was an exciting year in the clinical trials industry. We have seen many changes in patient connectivity and information exchange as well as digital health and AI implementation. The well-established fields of quality, risk management, and vendor oversight are moving cautiously into analytics. As we enter 2019, we discuss new trends that will continue to not only impact our businesses but will continue to shape the industry.
Today every company is a digital company. Rapidly evolving technology, new business models, regulatory uncertainty and changing payment models, combined with stringent demands from regulators and customers make build versus buy decisions critical and of major strategic importance, far beyond a simple cost comparison. Register to download this free white paper and gain some strategic insight on best practices for development decision-making, before you build or buy.
Today, state of the art is to achieve interoperability. Even industries that were ahead of us in integration are now struggling with advancing to true interoperability. Whether you are new to interoperability or currently considering partners for your integration strategy, CitiusTech and Adaptive-Clinical Systems can help guide your journey.
Having passed the one year mark since the placement of the installment of the ICH E6 R2 Addendum, we see additional clarity on risk identification and evaluation, risk control and review, risk monitoring and risk communication and reporting. Get an in-depth look at the results of this Addendum by registering to download this insightful white paper below.
Having passed the one year mark since the placement of the installment of the ICH E6 R2 Addendum, we see additional clarity on risk identification and evaluation, risk control and review, risk monitoring and risk communication and reporting. Get an in-depth look at the results of this Addendum by registering to download this insightful white paper below.
